ATE474592T1 - Zusammensetzungen enthaltend lipase, protease und amylase zur behandlung von pankreasinsuffizienz - Google Patents

Zusammensetzungen enthaltend lipase, protease und amylase zur behandlung von pankreasinsuffizienz

Info

Publication number
ATE474592T1
ATE474592T1 AT05814918T AT05814918T ATE474592T1 AT E474592 T1 ATE474592 T1 AT E474592T1 AT 05814918 T AT05814918 T AT 05814918T AT 05814918 T AT05814918 T AT 05814918T AT E474592 T1 ATE474592 T1 AT E474592T1
Authority
AT
Austria
Prior art keywords
treatment
amylase
protease
insufficiency
pancreasic
Prior art date
Application number
AT05814918T
Other languages
English (en)
Inventor
Alexey Margolin
Bhami Shenoy
Frederick Murray
Anthony Christopher Lee Stevens
Original Assignee
Altus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altus Pharmaceuticals Inc filed Critical Altus Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE474592T1 publication Critical patent/ATE474592T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT05814918T 2004-10-14 2005-10-14 Zusammensetzungen enthaltend lipase, protease und amylase zur behandlung von pankreasinsuffizienz ATE474592T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61876404P 2004-10-14 2004-10-14
PCT/US2005/036802 WO2006044529A1 (en) 2004-10-14 2005-10-14 Compositions containing lipase; protease and amylase for treating pancreatic insufficiency

Publications (1)

Publication Number Publication Date
ATE474592T1 true ATE474592T1 (de) 2010-08-15

Family

ID=35840531

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05814918T ATE474592T1 (de) 2004-10-14 2005-10-14 Zusammensetzungen enthaltend lipase, protease und amylase zur behandlung von pankreasinsuffizienz

Country Status (23)

Country Link
US (1) US7718169B2 (de)
EP (2) EP1809320B1 (de)
JP (1) JP4908420B2 (de)
KR (1) KR101333664B1 (de)
CN (1) CN101068565B (de)
AT (1) ATE474592T1 (de)
AU (1) AU2005295754B2 (de)
BR (1) BRPI0516515B1 (de)
CA (1) CA2584069C (de)
CY (2) CY1110838T1 (de)
DE (1) DE602005022471D1 (de)
DK (2) DK1809320T3 (de)
ES (2) ES2614157T3 (de)
HR (1) HRP20161684T1 (de)
HU (1) HUE031245T2 (de)
LT (1) LT2198880T (de)
MX (1) MX2007004534A (de)
PL (2) PL1809320T3 (de)
PT (2) PT2198880T (de)
RU (1) RU2385736C2 (de)
SI (2) SI1809320T1 (de)
UA (1) UA91521C2 (de)
WO (1) WO2006044529A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
CA2560613C (en) 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
WO2006002453A2 (en) * 2004-07-07 2006-01-12 Biodevelops Pharma Entwicklung Gmbh Use of a deubiquitinating compound for enhancing the expression of membrane proteins on the cell surface
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
PL2278002T3 (pl) 2005-07-29 2017-12-29 Abbott Laboratories Gmbh Pankreatyna o zmniejszonej zawartości wirusowej
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
WO2007053619A2 (en) 2005-11-01 2007-05-10 Bio-Cat, Inc. A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
JP5406040B2 (ja) 2006-12-21 2014-02-05 ノボザイムス アクティーゼルスカブ 医薬使用のためのリパーゼ変異体
US20080199448A1 (en) * 2007-02-16 2008-08-21 Ross Mairi R Enzyme composition for improving food digestion
RU2445952C2 (ru) * 2007-02-20 2012-03-27 Юранд Фармасьютикалз Лимитед Стабильные композиции пищеварительных ферментов
PT2079445E (pt) 2007-02-20 2016-02-29 Allergan Pharmaceuticals Internat Ltd Composições de enzimas digestivas estáveis
WO2009109856A2 (en) 2008-03-07 2009-09-11 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) * 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
EP2328609A1 (de) * 2008-08-26 2011-06-08 Cystic Fibrosis Foundation Therapeutics, Inc. Schnell auflösende tabletten mit lipase, amylase und protease
EP2165717A1 (de) 2008-08-27 2010-03-24 Nordmark Arzneimittel GmbH & Co.KG Verfahren zur Verringerung der viralen und mikrobiellen Belastung feststoffhaltiger biologischer Extrakte
EP2328566A1 (de) * 2008-09-30 2011-06-08 DSM IP Assets B.V. Enzymzusammensetzung und deren anwendung bei der behandlung von pankreasinsuffizienz
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CA2747703C (en) 2009-01-06 2021-06-15 Curemark Llc Compositions and methods for the treatment or the prevention of infections by e. coli
JP5684725B2 (ja) 2009-01-06 2015-03-18 キュレロン リミテッド ライアビリティ カンパニー 黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法
AU2015252099B2 (en) * 2009-01-06 2017-08-10 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
BRPI0922653B8 (pt) 2009-01-29 2021-05-25 Nordmark Arzneimittel Gmbh & Co Kg uso de uma lipase bacteriana do tipo pseudomonas em solução aquosa
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2010130622A1 (en) * 2009-05-11 2010-11-18 Dsm Ip Assets B.V. Enzyme composition for the treatment of prancreatic insufficiency
PL2295039T5 (pl) 2009-08-28 2023-02-27 Nordmark Pharma Gmbh Sposób wytwarzania granulek zawierających pankreatynę, w szczególności mikrogranulek zawierających pankreatynę, oraz wytworzone tym sposobem granulki zawierające pankreatynę
AU2016216662B2 (en) * 2009-09-17 2017-09-07 Allergan Therapeutics LLC Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
US8784884B2 (en) * 2009-09-17 2014-07-22 Stephen Perrett Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
US9511125B2 (en) * 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
WO2011072069A2 (en) * 2009-12-08 2011-06-16 Depomed, Inc. Gastric retentive pharmaceutical compositions for extended release of polypeptides
RU2429291C1 (ru) * 2009-12-28 2011-09-20 Российская Федерация, от имени которой выступает Министерство образования и науки Российской Федерации (Минобрнауки России) Пищеварительное средство на основе ферментов микробного происхождения
JP2011162491A (ja) * 2010-02-10 2011-08-25 Ezaki Glico Co Ltd 乾燥麹抽出物及びこれを用いた口腔用組成物
SE535296C2 (sv) * 2010-09-08 2012-06-19 Anara Ab Mognad av mag-tarmkanalen
EA029101B1 (ru) 2010-10-01 2018-02-28 Апталис Фарма Лимитид Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием
FR2966734B1 (fr) * 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides
EP2489349B1 (de) 2011-02-17 2014-05-28 Nordmark Arzneimittel GmbH & Co.KG Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und Verfahren zu deren Herstellung
DK2701733T3 (da) 2011-04-21 2019-05-27 Curemark Llc Forbindelser til behandling af neuropsykiatriske forstyrrelser
CA2843556A1 (en) 2011-08-08 2013-02-14 Aptalis Pharma Ltd. Method for dissolution testing of solid compositions containing digestive enzymes
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
IL313986B1 (en) 2012-02-17 2026-05-01 Alcresta Inc Methods, compositions and devices for supplying dietary fatty acid needs
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
PL3398594T3 (pl) * 2012-09-19 2024-11-04 Grespo Ab Kompozycje do ulepszenia funkcji mózgu
WO2014141121A1 (en) 2013-03-15 2014-09-18 Aptalis Pharma Ltd. Composition containing digestive enzymes and nutrients suitable for enteral administration
US9861681B2 (en) 2013-04-18 2018-01-09 The United States of America as represented by the Secretary of the Army, on behalf of the United States Army Medical Research Institute of Infectious Diseases Therapeutic compositions for neutralizing type I interferons, and methods of use
CA2919114A1 (en) 2013-07-22 2015-02-12 Aptalis Pharma Ltd. High potency pancreatin pharmaceutical compositions
EP3639846B1 (de) 2013-08-09 2022-09-28 Allergan Pharmaceuticals International Limited Verdauungsenzymzusammensetzung zur enteralen verabreichung
EP3003360B1 (de) 2013-11-05 2020-10-07 Allergan Pharmaceuticals International Limited Hochwirksame pharmazeutische pankreatinzusammensetzungen
JP2014193909A (ja) * 2014-06-04 2014-10-09 Nordmark Arzneimittel Gmbh & Co Kg 医薬調製物
EP3157568A1 (de) 2014-06-19 2017-04-26 Aptalis Pharma Limited Verfahren zur entfernung von viralen verunreinigungen aus pankreatischen extrakten
GB201501081D0 (en) 2015-01-22 2015-03-11 Cilian Ag Use of enzymes with a wide pH activity range as medicaments for promoting digestion
CN107407681B (zh) 2015-03-02 2020-06-30 东丽株式会社 胰功能异常的检测方法和检测用试剂盒
DE102015114859A1 (de) * 2015-09-04 2017-03-09 Nordmark Arzneimittel Gmbh & Co. Kg Verwendung einer pharmazeutischen Zusammensetzung, enthaltend mindestens ein Verdauungsenzym, bei der künstlichen Ernährung
US10258590B2 (en) 2015-10-14 2019-04-16 Alcresta Therapeutics, Inc. Enteral feeding device and related methods of use
DE102017104472A1 (de) * 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Schmelztablette enthaltend Burlulipase und daraus hergestellte pharmazeutische Zusammensetzung
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
US11045396B2 (en) 2017-08-17 2021-06-29 Alcresta Therapeutics, Inc. Devices and methods for the supplementation of a nutritional formula
FR3079146B1 (fr) 2018-03-23 2020-04-17 Karim Ioualalen Formulation gastroprotectrice de complexes d’enzymes permettant de restaurer la fonction digestive.
US11547745B1 (en) 2018-08-23 2023-01-10 Vets Plus, Inc. Compositions and methods for treating pancreatic enzyme deficiencies in mammals
BR112022003705A2 (pt) 2019-08-30 2022-05-24 Codexis Inc Lipase recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, composição farmacêutica para o tratamento de insuficiência pancreática, célula hospedeira, métodos para produzir uma lipase recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, e, uso
WO2021202363A1 (en) * 2020-03-30 2021-10-07 Wall Jai Combined animal-derived and synthetically produced pancreatic enzyme replacement therapy
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
EP4408990A2 (de) * 2021-09-30 2024-08-07 Anagram Therapeutics, Inc. Manipulierte lipaseenzyme, herstellung und verwendung davon
WO2025054130A1 (en) 2023-09-05 2025-03-13 The Regents Of The University Of California Enzymes for oxidizing beta-hydroxybutyrate (bhb), test strips, and sensors of using the same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5017559B2 (de) 1972-09-20 1975-06-21
JPS5428820Y2 (de) 1974-06-14 1979-09-14
GB1509866A (en) 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
US4659667A (en) 1985-02-26 1987-04-21 Miles Laboratories, Inc. Process to recover crystalline enzymes and crystalline enzymes produced thereby
DK154572C (da) 1985-08-07 1989-04-24 Novo Industri As Enzymatisk detergentadditiv, detergent og fremgangsmaade til vask af tekstiler
JP3079276B2 (ja) 1988-02-28 2000-08-21 天野製薬株式会社 組換え体ｄｎａ、それを含むシュードモナス属菌及びそれを用いたリパーゼの製造法
DE3808695A1 (de) 1988-03-16 1989-10-05 Henkel Kgaa Fluessiges waschmittel
EP0387945B1 (de) 1989-03-08 1993-11-03 Simon Lodewijk Scharpé Mischung zur Behandlung der von exokrinen Insuffizienz der Bauchspeicheldrüse und die Verwendung der genannten Mischung
JPH05502584A (ja) 1989-12-21 1993-05-13 ノボ　ノルディスク　アクティーゼルスカブ 酵素含有調製品及び該調製品を含有する洗剤
DK173590D0 (da) 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
AU662104B2 (en) 1990-08-03 1995-08-24 Vertex Pharmaceuticals Incorporated Use of crosslinked crystals as a novel form of enzyme immobilization
US5618710A (en) 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
US5892013A (en) 1990-09-13 1999-04-06 Novo Nordisk A/S Lipase variants
CA2110497C (en) 1991-07-01 2005-04-19 Reinhard Braatz Use of bacterial lipases for producing drugs for maldigestion therapy
WO1993013200A1 (en) 1991-12-20 1993-07-08 Novo Nordisk A/S A process for the preparation of lipase
SG42846A1 (en) 1992-06-30 1997-10-17 Cortecs Ltd Use of enzymes especially bromelain in the treatment of diarrhoea
DK154292D0 (da) 1992-12-23 1992-12-23 Novo Nordisk As Nyt enzym
DK39693D0 (da) 1993-04-02 1993-04-02 Novo Nordisk As Enzym
GB9403344D0 (en) 1994-02-22 1994-04-13 Cortecs Ltd Medical application of bromelain
DE4408152A1 (de) 1994-03-11 1995-09-14 Studiengesellschaft Kohle Mbh Immobilisierte Lipasen in hydrophoben Sol-Gel-Materialien
AU2524695A (en) 1994-05-04 1995-11-29 Genencor International, Inc. Lipases with improved surfactant resistance
DE69634248T2 (de) 1995-05-31 2006-01-12 Medzyme N.V. Zusammensetzungen zur verbesserung der verdaulichkeit und ausnutzung von nähestoffen
US5932212A (en) 1996-05-24 1999-08-03 Altus Biologics, Inc. Crosslinked protein crystal formulations and their use as catalysts in organic solvents
US5750104A (en) 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US6140475A (en) 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
DK1009759T3 (da) 1997-09-05 2008-08-04 Altus Pharmaceuticals Inc Carbohydrat-tværbundne glycoproteinkrystaller
US6013680A (en) 1997-10-21 2000-01-11 Amano Pharmaceutical Co., Ltd. Digestive enzyme-containing medicament
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6156552A (en) 1998-02-18 2000-12-05 Novo Nordisk A/S Lipase variants
EP2311436A1 (de) 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Stabilisierte Protein-Kristalle, diese enthaltende Formulierungen und ihre Herstellungsverfahren
US6042823A (en) 1998-07-02 2000-03-28 Amano Pharmaceuticals Co., Ltd. Enzyme composition and use thereof
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.

Also Published As

Publication number Publication date
CN101068565A (zh) 2007-11-07
KR101333664B1 (ko) 2013-11-28
MX2007004534A (es) 2007-11-08
BRPI0516515A (pt) 2008-09-16
AU2005295754A1 (en) 2006-04-27
US20060121017A1 (en) 2006-06-08
DK2198880T3 (en) 2017-01-23
SI2198880T1 (sl) 2017-02-28
DK1809320T3 (da) 2010-11-15
EP2198880B1 (de) 2016-11-23
KR20070074622A (ko) 2007-07-12
SI1809320T1 (sl) 2010-11-30
CY1118597T1 (el) 2017-07-12
CA2584069C (en) 2017-02-07
JP4908420B2 (ja) 2012-04-04
CN101068565B (zh) 2010-11-17
HK1109068A1 (en) 2008-05-30
HRP20161684T1 (hr) 2017-02-24
AU2005295754B2 (en) 2010-09-09
LT2198880T (lt) 2017-02-27
CY1110838T1 (el) 2015-06-10
RU2007117728A (ru) 2008-11-20
PT2198880T (pt) 2017-01-04
WO2006044529A1 (en) 2006-04-27
PL1809320T3 (pl) 2011-11-30
UA91521C2 (ru) 2010-08-10
PT1809320E (pt) 2010-10-25
US7718169B2 (en) 2010-05-18
HUE031245T2 (en) 2017-06-28
CA2584069A1 (en) 2006-04-27
EP1809320A1 (de) 2007-07-25
AU2005295754A2 (en) 2010-09-02
RU2385736C2 (ru) 2010-04-10
EP1809320B1 (de) 2010-07-21
ES2614157T3 (es) 2017-05-29
BRPI0516515B1 (pt) 2018-05-29
PL2198880T3 (pl) 2017-04-28
ES2352086T3 (es) 2011-02-15
EP2198880A1 (de) 2010-06-23
JP2008516965A (ja) 2008-05-22
DE602005022471D1 (de) 2010-09-02

Similar Documents

Publication Publication Date Title
DE602005022471D1 (de) Zusammensetzungen enthaltend lipase, protease und amylase zur behandlung von pankreasinsuffizienz
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
ATE540950T1 (de) Aminocyclohexane als dipeptidylpeptidase-iv- hemmer zur behandlung bzw. prävention von diabetes
ATE439863T1 (de) Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie
ZA200705177B (en) Lyophilization of virosomes
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
DK1779858T3 (da) Anvendelse af selenforbindelser, især selengær, til forandring af kognitiv funktion
ATE542536T1 (de) 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen
DE60335647D1 (de) Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden
ATE446754T1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
DE60313803D1 (de) Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen
ATE519504T1 (de) Chromatin-remodellierende substanzen zur erhöhung der expression von pdx-1 und förderung der zelldifferenzierung
DE602006009786D1 (de) Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten
ATE473277T1 (de) Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten
EA200601392A1 (ru) Способы и композиции для лечения липодистрофии
DE602005016697D1 (de) Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen
ATE506069T1 (de) Verfahren und zusammensetzung zur modulation des systemischen entzündlichen reaktionssyndroms (sirs)
DE502004012196D1 (de) Verwendung von isorhamnetin zur behandlung von depressiven verstimmungen und erkrankungen
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
ATE427754T1 (de) Verwendung von il-17f zur behandlung und/oder pravention von neurologischen erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1809320

Country of ref document: EP